Franklin Resources Inc. Sells 37,070 Shares of Regeneron Pharmaceuticals Inc (REGN)

Franklin Resources Inc. trimmed its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 5.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 652,885 shares of the biopharmaceutical company’s stock after selling 37,070 shares during the period. Franklin Resources Inc.’s holdings in Regeneron Pharmaceuticals were worth $263,792,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Icon Wealth Partners LLC purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $112,000. Signaturefd LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 123.8% during the second quarter. Signaturefd LLC now owns 358 shares of the biopharmaceutical company’s stock valued at $124,000 after purchasing an additional 198 shares during the last quarter. Flagship Harbor Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $159,000. Columbia Asset Management purchased a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $196,000. Finally, Valeo Financial Advisors LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 943.4% during the second quarter. Valeo Financial Advisors LLC now owns 553 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 500 shares during the last quarter. Hedge funds and other institutional investors own 66.83% of the company’s stock.

Shares of NASDAQ REGN opened at $365.65 on Friday. Regeneron Pharmaceuticals Inc has a twelve month low of $281.89 and a twelve month high of $416.49. The company has a market capitalization of $38.91 billion, a P/E ratio of 19.71, a PEG ratio of 1.54 and a beta of 1.34. The company has a quick ratio of 3.30, a current ratio of 4.04 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported $5.87 earnings per share for the quarter, topping analysts’ consensus estimates of $4.94 by $0.93. Regeneron Pharmaceuticals had a net margin of 28.24% and a return on equity of 30.24%. The company had revenue of $1.66 billion during the quarter, compared to analyst estimates of $1.64 billion. During the same period in the previous year, the business earned $3.99 EPS. The firm’s revenue for the quarter was up 10.8% on a year-over-year basis. Sell-side analysts expect that Regeneron Pharmaceuticals Inc will post 19.48 earnings per share for the current fiscal year.

In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 2,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, September 27th. The shares were sold at an average price of $392.26, for a total value of $784,520.00. Following the completion of the sale, the director now owns 2,000 shares of the company’s stock, valued at approximately $784,520. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Sanofi sold 104,552 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, September 6th. The stock was sold at an average price of $406.68, for a total transaction of $42,519,207.36. The disclosure for this sale can be found here. In the last ninety days, insiders sold 108,552 shares of company stock valued at $44,081,027. 12.42% of the stock is currently owned by insiders.

REGN has been the subject of several recent research reports. Leerink Swann lifted their target price on shares of Regeneron Pharmaceuticals from $506.00 to $512.00 and gave the company an “outperform” rating in a report on Monday, October 1st. ValuEngine upgraded shares of Regeneron Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, September 6th. BidaskClub upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, September 1st. Morgan Stanley lifted their target price on shares of Regeneron Pharmaceuticals from $409.00 to $412.00 and gave the company an “equal weight” rating in a report on Thursday, October 11th. Finally, Cantor Fitzgerald lifted their target price on shares of Regeneron Pharmaceuticals to $441.00 and gave the company a “neutral” rating in a report on Monday, October 22nd. Two research analysts have rated the stock with a sell rating, seventeen have issued a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $402.37.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2018/12/01/franklin-resources-inc-sells-37070-shares-of-regeneron-pharmaceuticals-inc-regn.html.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

See Also: Preferred Stock

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit